SCHEMBL20401337

SCHEMBL20401337

CC(=O)c1cccc(Cn2cc(B3OC(C)(C)C(C)(C)O3)cn2)n1

nearest known ligand 0.51

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.51
KLKB1 P03952 7/20 0.38
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
IRAK4 Q9NWZ3 2/20 0.34
LIPG Q9Y5X9 1/20 0.33
TAS2R8 Q9NYW2 2/20 0.33
SCD O00767 1/20 0.32
SCD5 Q86SK9 1/20 0.32
DGAT1 O75907 1/20 0.32
UCHL1 P09936 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17247588 0.83 FFAR1 (0.52) FFAR1KLKB1HDAC1HDAC2IRAK4
SCHEMBL15885161 0.82 FFAR1 (0.50) FFAR1KLKB1HDAC1HDAC2IRAK4
SCHEMBL20401265 0.80 FFAR1 (0.57) FFAR1KLKB1IRAK4DGAT1
SCHEMBL15885095 0.79 FFAR1 (0.47) FFAR1KLKB1IRAK4LIPGTAS2R8
SCHEMBL18996856 0.78 FFAR1 (0.49) FFAR1KLKB1IRAK4LIPGTAS2R8
SCHEMBL20436375 0.78 HDAC1 (0.42) KLKB1HDAC1HDAC2IRAK4TAS2R8
SCHEMBL2825716 0.77 KLKB1 (0.46) KLKB1HDAC1HDAC2IRAK4
SCHEMBL20416533 0.77 HDAC1 (0.39) KLKB1HDAC1HDAC2IRAK4TAS2R8
SCHEMBL16754201 0.76 FFAR1 (0.44) FFAR1IRAK4
SCHEMBL29801233 0.76 FFAR1 (0.44) FFAR1IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12195447-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. (US) 2025-01-14 US disclosed
EP-4310082-A2 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS Arcus Biosciences, Inc. (US) 2024-01-24 EP disclosed
EP-3570844-B1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES INC (US) 2023-09-06 EP disclosed
US-20220144808-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2022-05-12 US disclosed
US-11072597-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. 2021-07-27 US disclosed
US-20210101880-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2021-04-08 US disclosed
US-10399962-B2 Azolopyrimidine for the treatment of cancer-related disorders ARCUS BIOSCIENCES, INC. (US) 2019-09-03 US disclosed
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. 2018-08-02 US disclosed
WO-2018136700-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ARCUS BIOSCIENCES, INC. (US) 2018-07-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144808-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 FFAR1 1017/4885KLKB1 1782/4885HDAC1 3195/4885
US-11072597-B2 Azolopyrimidine for the treatment of cancer-related disorders ADORA2A, ADORA2B, ADORA1 FFAR1 1017/4885KLKB1 1782/4885HDAC1 3195/4885
US-12195447-B2 Azolopyrimidine for the treatment of cancer-related disorders ADORA2A, ADORA2B, ADORA1 FFAR1 1017/4885KLKB1 1782/4885HDAC1 3195/4885
US-20180215730-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 FFAR1 1017/4885KLKB1 1782/4885HDAC1 3195/4885
US-10399962-B2 Azolopyrimidine for the treatment of cancer-related disorders ADORA2A, ADORA2B, ADORA1 FFAR1 1017/4885KLKB1 1782/4885HDAC1 3195/4885
US-20210101880-A1 AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS ADORA2A, ADORA2B, ADORA1 FFAR1 1017/4885KLKB1 1782/4885HDAC1 3195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.